Acute lymphoblastic leukemia natural history, complications and prognosis
|
Acute lymphoblastic leukemia Microchapters |
|
Differentiating Acute lymphoblastic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute lymphoblastic leukemia natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Acute lymphoblastic leukemia natural history, complications and prognosis |
|
FDA on Acute lymphoblastic leukemia natural history, complications and prognosis |
|
CDC on Acute lymphoblastic leukemia natural history, complications and prognosis |
|
Acute lymphoblastic leukemia natural history, complications and prognosis in the news |
|
Blogs on Acute lymphoblastic leukemia natural history, complications and prognosis |
|
Directions to Hospitals Treating Acute lymphoblastic leukemia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]
Prognosis
The overall cure rate in children is 85%, and about 50% of adults have long-term disease-free survival.[1][2]
Advancements in medical technology and research over the past four decades in the treatment of ALL has improved the overall prognosis significantly from a zero to 20-75 percent survival rate, largely due to the continuous development of clinical trials and improvements in bone marrow transplantation (BMT) and stem cell transplantation (SCT) technology.
It is worth noting that medical advances in recent years, both through matching the best treatment to the genetic characteristics of the blast cells and through the availability of new drugs, are not fully reflected in statistics that usually refer to five-year survival rates. The prognosis for ALL differs between individuals depending on a wide variety of factors:
- Gender: Females tend to fare better than males.
- Ethnicity: Caucasians are more likely to develop acute leukemia than African-Americans, Asians and Hispanics and tend to have a better prognosis than non-Caucasians.
- Age at diagnosis: Age is a significant factor in children with Acute lymphoblastic leukemia and may be an important prognostic factor in adult Acute lympoblastic leukemia. In one study, overall, the prognosis was better in patients younger than 25 years; another study found a better prognosis in patients younger than 35 years. These findings may, in part, be related to the increased incidence of the Ph1 in older Acute lymphoblatic leukemia patients, a subgroup associated with poor prognosis. Children between 1-10 years of age are most likely to be cured.
- White blood cell count at diagnosis of less than 50,000/µl
- Whether the cancer has spread to the brain or spinal cord
- Morphological, immunological, and genetic subtypes
- Response of patient to initial treatment
- Genetic disorders such as Down's Syndrome
Some cytogenetic subtypes have a worse prognosis than others. These include:
- A translocation between chromosomes 9 and 22, known as the Philadelphia chromosome, occurs in about 20% of adult and 5% in pediatric cases of ALL.
- A translocation between chromosomes 4 and 11 occurs in about 4% of cases and is most common in infants under 12 months.
- Not all translocations of chromosomes carry a poorer prognosis. Some translocations are relatively favorable. For example, hyperdiploidy (>50 chromosomes) is a good prognostic factor.
5-Year Survival
- Between 2004 and 2010, the 5-year relative survival of patients with ALL was 70%.[3]
- When stratified by age, the 5-year relative survival of patients with ALL was 71.3% and 12.2% for patients <65 and ≥ 65 years of age respectively.[3]
References
- ↑ Harrison's Principles of Internal Medicine, 16th Edition, Chapter 97. Malignancies of Lymphoid Cells. Clinical Features, Treatment, and Prognosis of Specific Lymphoid Malignancies.
- ↑ "National Cancer Institute".
- ↑ 3.0 3.1 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.